📊 MGRX Key Takeaways
Is Mangoceuticals, Inc.. (MGRX) a Good Investment?
Mangoceuticals faces imminent going concern risk with revenue collapsed 26% YoY to $67.9K while burning $1.3M quarterly in operations, leaving only $174.6K cash (6-8 weeks runway). The company is destroying shareholder value with -5014.7% net margin and -23.6% ROA, indicating fundamental operational failure at current scale.
Mangoceuticals shows extremely weak fundamentals: revenue is small and declining, while operating and net losses are massively larger than sales, indicating the business model is not close to sustainable at its current scale. Although the balance sheet has low liabilities and no meaningful debt, ongoing cash burn relative to its cash position creates substantial execution and financing risk unless revenue growth and cost discipline improve materially.
Why Buy Mangoceuticals, Inc.. Stock? MGRX Key Strengths
- Reasonable gross margin of 42.7% suggests viable unit economics if revenue could scale
- Minimal debt burden (0.00x debt/equity) prevents leverage amplification of distress
- Positive shareholders' equity of $13.5M provides limited balance sheet buffer
- Debt-free balance sheet with very low leverage
- Positive gross margin suggests the core product can generate unit-level gross profit
- Current ratio above 1.0 indicates near-term obligations are manageable for now
MGRX Stock Risks: Mangoceuticals, Inc.. Investment Risks
- Critical liquidity crisis: current ratio of 0.29x with $174.6K cash against $1.3M quarterly burn rate indicates 6-8 weeks operational runway without capital injection
- Revenue collapse of 26% YoY to $67.9K magnitude signals fundamental business model failure or market rejection
- Severe unprofitability with -5014.7% net margin and -23.6% ROA demonstrates complete operational inefficiency at current revenue scale
- Revenue declined 26.0% year over year, pointing to weak growth quality and limited operating traction
- Operating loss of $18.03M on just $456.02K of revenue shows extreme cost imbalance and no operating leverage
- Operating cash outflow of $5.85M versus $1.49M cash implies meaningful liquidity pressure if burn continues
Key Metrics to Watch
- Cash balance and monthly burn rate (going concern threshold)
- Revenue stabilization and month-over-month growth trajectory
- Capital injection announcement or operating cash flow path to breakeven
- Quarterly revenue growth and gross profit dollars
- Operating cash burn relative to ending cash balance
Mangoceuticals, Inc.. (MGRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MGRX Profit Margin, ROE & Profitability Analysis
MGRX vs Services Sector: How Mangoceuticals, Inc.. Compares
How Mangoceuticals, Inc.. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mangoceuticals, Inc.. Stock Overvalued? MGRX Valuation Analysis 2026
Based on fundamental analysis, Mangoceuticals, Inc.. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mangoceuticals, Inc.. Balance Sheet: MGRX Debt, Cash & Liquidity
MGRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mangoceuticals, Inc..'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-4.80 indicates the company is currently unprofitable.
MGRX Revenue Growth, EPS Growth & YoY Performance
MGRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $67.9K | -$3.4M | $-0.22 |
| Q3 2025 | $84.2K | -$2.0M | $-0.69 |
| Q2 2025 | $163.2K | -$2.4M | $-0.57 |
| Q1 2025 | $109.3K | -$2.4M | $-1.29 |
| Q3 2024 | $133.4K | -$1.8M | $-0.99 |
| Q2 2024 | $141.2K | -$2.3M | $-0.09 |
| Q1 2024 | $100.7K | -$2.4M | $-0.10 |
| Q3 2023 | $245.2K | -$19.6K | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Mangoceuticals, Inc.. Dividends, Buybacks & Capital Allocation
MGRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mangoceuticals, Inc.. (CIK: 0001938046)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MGRX
What is the AI rating for MGRX?
Mangoceuticals, Inc.. (MGRX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGRX's key strengths?
Claude: Reasonable gross margin of 42.7% suggests viable unit economics if revenue could scale. Minimal debt burden (0.00x debt/equity) prevents leverage amplification of distress. ChatGPT: Debt-free balance sheet with very low leverage. Positive gross margin suggests the core product can generate unit-level gross profit.
What are the risks of investing in MGRX?
Claude: Critical liquidity crisis: current ratio of 0.29x with $174.6K cash against $1.3M quarterly burn rate indicates 6-8 weeks operational runway without capital injection. Revenue collapse of 26% YoY to $67.9K magnitude signals fundamental business model failure or market rejection. ChatGPT: Revenue declined 26.0% year over year, pointing to weak growth quality and limited operating traction. Operating loss of $18.03M on just $456.02K of revenue shows extreme cost imbalance and no operating leverage.
What is MGRX's revenue and growth?
Mangoceuticals, Inc.. reported revenue of $67.9K.
Does MGRX pay dividends?
Mangoceuticals, Inc.. does not currently pay dividends.
Where can I find MGRX SEC filings?
Official SEC filings for Mangoceuticals, Inc.. (CIK: 0001938046) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGRX's EPS?
Mangoceuticals, Inc.. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mangoceuticals, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGRX stock overvalued or undervalued?
Valuation metrics for MGRX: ROE of -25.3% (sector avg: 16%), net margin of -5,014.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy MGRX stock in 2026?
Our dual AI analysis gives Mangoceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGRX's free cash flow?
Mangoceuticals, Inc..'s operating cash flow is $-1.3M, with capital expenditures of $3.5K. FCF margin is -1,937.5%.
How does MGRX compare to other Services stocks?
Vs Services sector averages: Net margin -5,014.7% (avg: 10%), ROE -25.3% (avg: 16%), current ratio 0.29 (avg: 1.5).